DuPont de Nemours, Inc. filings document the regulatory disclosures of a Delaware specialty materials company with common stock listed on the New York Stock Exchange under DD. Its 8-K reports cover operating and financial results, Regulation FD disclosures, material events, board composition changes, corporate-governance matters and capital-structure disclosures.
DuPont proxy materials describe annual stockholder voting matters, director elections, governance practices, executive compensation and proposals affecting the company’s certificate of incorporation and common stock. Recent filings also document separation-related matters, including disclosures connected with the completed Qnity Electronics spin-off, as well as agreements and percentage calculations tied to the post-separation corporate structure.
DuPont de Nemours, Inc. officer Edward D. Breen gave notice of a proposed sale of 89,845 common shares, with an aggregate market value of $13,154,896.25, dated November 5, 2026. The shares are listed in connection with exercise of employee stock options. The notice also lists 132,532,338 common shares outstanding.
DuPont de Nemours, Inc. (DD) reported third-quarter 2026 net sales of $1.868 billion, compared with $1.795 billion a year earlier, and income from continuing operations of $171 million, versus $102 million. Net income available for DuPont common stockholders was $123 million, compared with a $123 million loss.
For the nine months ended September 30, 2026, income from continuing operations was $512 million versus $206 million, while cash provided by continuing operating activities was $1.042 billion versus $473 million. At September 30, 2026, cash and cash equivalents were $1.652 billion and long-term debt was $3.094 billion.
DuPont completed the Aramids business sale on April 1, 2026, in a transaction for gross consideration of $1.8 billion. At closing, it received approximately $1.2 billion in pre-tax cash proceeds, a $300 million note receivable, and an approximately 16% non-controlling common equity interest in Arclin valued at $325 million. DuPont recorded a total $378 million loss on the sale, including an $82 million gain recognized in the second quarter when the disposal group's carrying value was finalized. The Aramids and previously separated Electronics businesses are presented as discontinued operations.
DuPont de Nemours, Inc. (DD) reported third-quarter 2026 net sales of $1.868 billion, up 4% year over year, while organic sales rose 5%. Income from continuing operations was $171 million, up 68%; operating EBITDA was $469 million, up 8%; and adjusted EPS was $2.09, up 62%. Cash provided by operating activities from continuing operations was $410 million, and transaction-adjusted free cash flow was $341 million, with transaction-adjusted free cash flow conversion of 121%. Including discontinued operations, net income was $126 million versus a $107 million net loss a year earlier.
Management raised full-year 2026 outlook to about 4.5% organic growth, about $1.785 billion of operating EBITDA and adjusted EPS of $7.47-$7.52 per share. Healthcare & Water Technologies sales rose 4% and EBITDA 7%; Diversified Industrials sales rose 4% and EBITDA 11%. DuPont completed a $250 million accelerated share purchase and substantially completed $100 million of open-market share repurchases in the quarter; it announced intent to repurchase $250 million of shares in the fourth quarter.
DuPont de Nemours, Inc. (DD) entered into a Settlement Agreement with the State of North Carolina and 11 local entities, together with Chemours and Corteva, to resolve claims relating to PFAS and other emissions from the Fayetteville Works facility and certain PFAS contamination elsewhere, including uses of aqueous film-forming foam. The Settlement provides for an aggregate $455 million cash payment to the plaintiffs over 15 years, shared among the companies under their 2021 Memorandum of Understanding. Of this amount, $18 million is attributed to alleged PFAS contamination unrelated to Fayetteville Works, with no more than $14.4 million tied to AFFF. DuPont previously recorded a probable loss of about $125 million (pre-tax net present value) in discontinued operations for its share, before a 44% reimbursement obligation from Qnity Electronics Inc., and notes that this is materially covered by existing accruals. DuPont and Corteva will also provide a $135 million reserve fund as financial security if Chemours does not perform under a 2019 Consent Order. The companies have agreed how this and potential future PFAS settlements will be valued under their cost-sharing MOU, and North Carolina and New Jersey settlement payments will fully satisfy their future MOU escrow contribution obligations, including the contribution otherwise due in September 2026.
DuPont de Nemours, Inc. (DD) director Donald G. Macpherson reported an acquisition of common stock. On 2026-08-28, he received a grant/award of 237.2609 shares of DuPont common stock at a reported value of $136.98 per share, including shares acquired through dividend reinvestment. Following this transaction, his directly held stake increased to 2,195.8595 shares of common stock.
DuPont de Nemours, Inc. (DD) reported that director Frederick M. Lowery received a grant/award of 282.888 shares of Common Stock on 2026-08-28 at a reported value of $136.98 per share. Following this acquisition, his directly held position increased to 13,862.3372 shares, including shares acquired through dividend reinvestment.
DuPont de Nemours, Inc. (DD) director Alexander M. Cutler reported an automatic acquisition of common stock. On 2026-08-28, he received 365.0168 shares of common stock as a grant or award, which includes shares acquired pursuant to dividend reinvestment. Following this transaction, his directly held position increased to 25,154.7973 shares of DuPont common stock.
DuPont de Nemours, Inc. (DD) director Edward D. Breen reported two Form 4 transactions involving gifts of common stock. On August 17, 2026, he disposed of 34,485 shares as a bona fide gift to fund a new GRAT 2026-3. On August 25, 2025, he acquired 53,000 shares as annuity payments from prior GRATs, also reported as bona fide gifts. The earlier GRAT-related transactions were reported late due to an inadvertent administrative error, and share amounts were adjusted for a June 1, 2026 reverse stock split.
DuPont de Nemours, Inc. is conducting an Exchange Offer to swap up to $684,398,000 principal amount of its privately placed 4.725% Notes due 2028 for an equal principal amount of new 4.725% Notes due 2028 registered under the Securities Act. The Exchange Notes have the same financial terms and covenants as the Original Notes but will be freely tradable, while any untendered Original Notes will remain restricted securities and may become less liquid.
The Exchange Notes are senior unsecured obligations, are not guaranteed by subsidiaries, and rank effectively junior to any secured or subsidiary debt; as of June 30, 2026, subsidiaries had $9 million of debt structurally senior to the Notes. Holders face risks from potential interest rate increases, limited or no trading market, and change-of-control mechanics under which a qualifying Change of Control Triggering Event gives a put right at 101% of principal plus interest, subject to DuPont’s ability to fund repurchases.
DuPont completed a 1-for-3 reverse stock split effective June 24, 2026, and share and earnings data have been recast. For 2025, income from continuing operations attributable to common stockholders was $88 million, with basic EPS from continuing operations of $0.63 and a total basic EPS of $(5.60) after discontinued operations. Weighted-average basic shares were 139.2 million in 2025, and common shares outstanding were 136,398,482 at year-end 2025. The exchange is structured to satisfy DuPont’s Registration Rights Agreement and will not change total indebtedness or generate cash proceeds.